Page 226 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

19 has spread worldwide [1]. The World Health Organization (WHO) declared COVID-19 a public

health emergency of international concern and a global pandemic, posing a severe threat to global

public security [2]. According to WHO data, 33,842,281 confirmed cases of COVID-19 were
reported worldwide as of October 1, 2020, including 1,010,634 deaths [2]. The pathogen causing

COVID-19 pneumonia is a coronavirus, and the virus was officially named SARS-CoV-2 by WHO
on February 11, 2020 [3]. SARS-CoV-2 has high infectivity and concealment [4], making it difficult

to treat viral infectious diseases at the clinic.

Asthma is a recurrent chronic airway inflammatory disease and the most common chronic

respiratory disease globally [5,6]. More than 339 million people have asthma worldwide. Asthma

has become a severe public health problem, and approximately 250,000 people die yearly [7,8].

Compared with healthy people, asthma patients are easily infected with respiratory viruses, with

adenovirus, bocavirus, and coronavirus being the most common [9]. Thus, COVID-19 may lead to

increased exacerbation of asthma. A study on the clinical characteristics of patients with COVID-

19 pneumonia showed that the incidence of severe pneumonia and the proportion of admission to

the intensive care units significantly increased for patients with chronic respiratory diseases [10].

However, the specific mechanisms underlying COVID-19/asthma comorbidity are unknown.
The aim of this study is to analyze the relationship between COVID-19 and asthma co-

occurrence and identify potential biomarkers for COVID-19 and asthma through bioinformatic
analysis. This study provides new insights into the molecular mechanisms of COVID-19/asthma

comorbidity and may lay a theoretical foundation for therapeutic development in COVID-19/asthma

comorbidity. The flowchart of this study is illustrated in Figure 1.

- 221 -